An aid to a better understanding of the definitions of BCG failure provided by the European Urology Association

February 2023 in “ Actas Urológicas Españolas (English Edition) ”

J. Huguet Pérez, Ó. Rodríguez Faba, J.M. Gaya Sopena, Juan Palou Redorta, Alberto Breda

We don't know much about this study yet.

We're maintaining the world's largest resposity of hair loss research. You can help out the community by sending a PDF of this study here . Not sure how to get a study's PDF? You can email the authors of the study.

View this study on sciencedirect.com →

Discuss this study in the Community →

Related Community Posts Join

6 / 1000+ results

community Wrap it up everyone. CB-03-01 is another failed treatment

in Treatment 81 upvotes 6 months ago

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

community Bicalutamide vs Finasteride for female AGA plus TE

in Female 3 upvotes 1 month ago

OP is considering Bicalutamide for female AGA and TE but is concerned about its side effects and effectiveness compared to Finasteride. OP is also using Minoxidil and Spironolactone but is experiencing significant shedding and is unsure if it's androgen-driven or due to Minoxidil changes.

community FCE 28260: A Forgotten 5α-Reductase Inhibitor

in Research 330 upvotes 1 year ago

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

community Future hope ? What do you guys predict ? clascoterone, pyrilutamide, gt20029 etc.

in Treatment 15 upvotes 4 years ago

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

community Meta analysis: Topical or mesotherapy dutasteride is more effective than topical finasteride in the treatment of AGA in men

in Research/Science 17 upvotes 4 years ago

Topical Dutasteride is more effective than topical Finasteride for treating AGA in men, with fewer side effects. Mesotherapy with Dutasteride, administered every 3 months, shows promising results for hair regrowth and maintenance without daily routines or significant side effects.

community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

in Research/Science 135 upvotes 1 year ago

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.